Repligen (NASDAQ:RGEN) Shares Up 6.1% – Still a Buy?

Repligen Co. (NASDAQ:RGEN)’s stock price shot up 6.1% during trading on Wednesday . The stock traded as high as $136.85 and last traded at $136.27. 327,141 shares were traded during trading, a decline of 51% from the average session volume of 667,443 shares. The stock had previously closed at $128.49.

Analyst Ratings Changes

RGEN has been the subject of a number of recent research reports. Benchmark restated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. UBS Group dropped their price objective on shares of Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, July 31st. Wells Fargo & Company initiated coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and issued a $205.00 price objective on shares of Repligen in a research note on Thursday, September 26th. Finally, Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Repligen has an average rating of “Moderate Buy” and an average price target of $190.25.

Repligen Stock Up 0.6 %

The company has a debt-to-equity ratio of 0.26, a quick ratio of 5.56 and a current ratio of 10.44. The stock has a market capitalization of $7.99 billion, a price-to-earnings ratio of -382.12, a P/E/G ratio of 3.87 and a beta of 0.96. The firm’s fifty day simple moving average is $140.20 and its 200 day simple moving average is $143.62.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million for the quarter, compared to the consensus estimate of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The business’s quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the company posted $0.23 EPS. On average, sell-side analysts forecast that Repligen Co. will post 1.52 earnings per share for the current year.

Insider Activity

In related news, Director Anthony Hunt sold 22,191 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares of the company’s stock, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Repligen

Several institutional investors and hedge funds have recently modified their holdings of the stock. Champlain Investment Partners LLC lifted its position in Repligen by 149.0% during the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after purchasing an additional 850,345 shares during the period. Bank of New York Mellon Corp lifted its holdings in shares of Repligen by 21.0% in the second quarter. Bank of New York Mellon Corp now owns 1,370,375 shares of the biotechnology company’s stock worth $172,749,000 after acquiring an additional 237,884 shares during the last quarter. Conestoga Capital Advisors LLC lifted its holdings in shares of Repligen by 26.7% in the second quarter. Conestoga Capital Advisors LLC now owns 946,877 shares of the biotechnology company’s stock worth $119,363,000 after acquiring an additional 199,322 shares during the last quarter. Thrivent Financial for Lutherans lifted its holdings in shares of Repligen by 6.1% in the third quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company’s stock worth $95,037,000 after acquiring an additional 36,773 shares during the last quarter. Finally, DF Dent & Co. Inc. lifted its holdings in shares of Repligen by 31.0% in the third quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock worth $87,852,000 after acquiring an additional 139,615 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.